NCT03881644

PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Danish Headache Center · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

Detailed description

Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced. The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.

Conditions

• Migraine Without Aura

Interventions

Type	Name	Description
DRUG	Imigran	All patients will undergo this intervention on one of two study days
OTHER	Isotonic Saline	All patients will undergo this intervention on one of two study days
OTHER	Pituitary adenylate cyclase-activating peptide-38	All patients will undergo this intervention on both study days

Timeline

• Start date: 2018-07-17
• Primary completion: 2019-12-07
• Completion: 2019-12-07
• First posted: 2019-03-19
• Last updated: 2020-06-22

Locations

1 site across 1 country: Denmark